|
Jul 18
|
J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?
|
|
Jul 18
|
Epilepsy Therapeutics Market Trends, Competitive Strategies and Forecasts Report 2025-2033 | Personalized Medicine Paves New Pathways in Treatment, Third-Generation Therapeutics Lead Growth
|
|
Jul 17
|
Pfizer (PFE) Expands Patient Access With Eliquis (Apixaban) Direct Purchase Program
|
|
Jul 17
|
Top Midday Stories: TSMC Lifts 2025 Revenue Growth Guidance; Lucid Partners With Uber on Robotaxi Launch
|
|
Jul 17
|
Nontuberculous Mycobacteria (NTM) Opportunity Assessment and Forecast to 2033 Featuring Janssen, Novartis, Meiji Seika Pharma, Insmed, Daiichi Sankyo, MannKind, Paratek, Nobelpharma, GSK, Pfizer
|
|
Jul 17
|
Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility
|
|
Jul 17
|
Pfizer Inc.'s (NYSE:PFE) recent 3.7% pullback adds to one-year year losses, institutional owners may take drastic measures
|
|
Jul 17
|
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients
|
|
Jul 17
|
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
|
|
Jul 17
|
Bristol-Myers and Pfizer to Offer Blockbuster Blood Thinner at Discount
|
|
Jul 17
|
Thyroid Gland Disorders Diagnostics and Treatment Market Analysis Report 2024-2030 | Incorporation of AI and Advanced Therapeutics Fueling Opportunities
|
|
Jul 16
|
Trump Threatens Pharma Tariffs Soon. Why the Stocks Are Looking Healthy.
|
|
Jul 16
|
Johnson & Johnson shares jump after forecasting sales boost and milder tariff impact
|
|
Jul 16
|
Mamdani Talks ‘Intifada’, Taxes in Grilling by Business Leaders
|
|
Jul 16
|
Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX)
|
|
Jul 16
|
Will Increased Expenses Affect Bristol Myers' Performance?
|
|
Jul 16
|
How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?
|
|
Jul 16
|
This Blue-Chip Stock Is 20% Off Its Highs. Should You Buy the Dip?
|
|
Jul 16
|
Leading Drug Delivery Conference PODD Announces its 15th Annual Agenda
|
|
Jul 16
|
This Once-Dominant Healthcare Stock Down 50% Is Finally Ready for a Comeback
|